Brian Berelowitz, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1356308357
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,794 of the $4,986 with a category attached, or 76.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $32.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$389
- Tandem Diabetes Care, Inc.$335
- Bayer$316
- AstraZeneca$259
- Ascendis Pharma Endocrinology Inc$248
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$3006%
- Food & beverage$3,79476%
- Education$89218%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $1,110 |
| Novo Nordisk | 18 | $389 |
| Tandem Diabetes Care, Inc. | 3 | $335 |
| Bayer | 13 | $316 |
| AstraZeneca(2 entities) | 13 | $259 |
| Ascendis Pharma Endocrinology Inc | 2 | $248 |
| Mannkind Corporation | 6 | $232 |
| Merck | 9 | $202 |
| Renalytix AI, Inc. | 1 | $188 |
| Sanofi-aventis U.S. LLC | 13 | $176 |
| Medtronic(2 entities) | 3 | $156 |
| Corcept Therapeutics | 2 | $142 |
| Neurocrine Biosciences, Inc. | 1 | $138 |
| BETA Bionics, Inc. | 2 | $134 |
| Chiesi USA, Inc. | 1 | $125 |
| Pfizer | 4 | $97 |
| Xeris Pharmaceuticals, Inc. | 5 | $85 |
| Lilly USA, LLC | 5 | $84 |
| Insulet Corporation | 4 | $79 |
| Radius Health, Inc. | 4 | $66 |
| Boston Scientific | 4 | $58 |
| AbbVie | 3 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Abbott | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Amryt Pharma Holdings Ltd | 2 | $26 |
| IBSA Pharma Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $12 |
| Dexcom, Inc. | 1 | $11 |
| Companion Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,986 in reported general payments places this provider in the 55th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 747 | $927,017 |
| OzempicSemaglutide | 252 | $358,289 |
| TrulicityDulaglutide | 172 | $274,753 |
| JardianceEmpagliflozin | 214 | $229,116 |
| Somatuline DepotLanreotide Acetate | 21 | $129,579 |
| Repatha SureclickEvolocumab | 153 | $124,637 |
| Tresiba Flextouch U-200Insulin Degludec | 150 | $115,291 |
| FarxigaDapagliflozin Propanediol | 109 | $110,509 |
| Tresiba Flextouch U-100Insulin Degludec | 246 | $106,549 |
| SynthroidLevothyroxine Sodium | 631 | $56,229 |
| ProliaDenosumab | 32 | $54,660 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $52,969 |
| JanuviaSitagliptin Phosphate | 45 | $48,913 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $46,792 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $43,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $84 | $1,219,221973 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $389 | $405,265351 claims |
| Boehringer IngelheimJardiance, Tradjenta | $32 | $252,829247 claims |
| AstraZenecaFarxiga | $259 | $110,509109 claims |
| AbbVieSynthroid, Creon | $49 | $70,611647 claims |
| MerckJanuvia, Janumet | $202 | $61,73960 claims |
| AmgenProlia | $1,110 | $54,66032 claims |
| BayerKerendia | $316 | $18,59518 claims |
| Antares Pharma, Inc.Xyosted | $12 | $16,86812 claims |
| IBSA Pharma Inc.Tirosint | $20 | $9,78833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.